Medtronic Raises Fiscal 2027 Forecasts Amid Rising Heart Device Demand

Medtronic has increased its fiscal 2027 revenue growth projections, citing robust demand for its heart devices used in complex cardiovascular procedures. The company has revised the lower end of its adjusted per share profit forecast to $5.94 from $5.90, maintaining the upper limit at $6. This adjustment reflects the company's confidence in the expanding adoption of its cardiovascular technologies and the overall strength of its business segments.

Strategic Investments Drive Growth

Medtronic's growth strategy includes significant investments in innovative technologies. The company announced an $80 million investment in Pi-Cardia, a heart-valve repair device maker, with an option to acquire the company for $210 million. Additionally, Medtronic invested $700 million in Cornerstone Robotics, securing distribution rights for a robotic surgical device in select markets outside the United States. These strategic moves are part of Medtronic's focus on high-growth medical technology segments with substantial patient pools.

CEO Geoff Martha highlighted the importance of these investments during a post-earnings call, noting that the company's confidence stems from the comprehensive performance across its business units and the contributions of new growth platforms. Martha also pointed out the under-penetration of soft tissue robotic surgery in emerging markets, with less than 1% adoption, emphasizing the potential for expansion.

Financial Performance and Market Outlook

Medtronic reported a 19.5% increase in quarterly sales for its cardiovascular segment, reaching $3.93 billion. This growth was largely driven by its pulsed field ablation portfolio, which experienced an 88% increase, underscoring the strong demand for innovative heart treatment solutions. The company posted an adjusted quarterly per share profit of $1.45 on revenue of $9.76 billion, surpassing estimates of $1.39 per share on $9.55 billion in sales, according to LSEG-compiled data.

Finance chief Thierry Pieton mentioned that tariff refunds nearly offset the duties paid during the quarter. However, these refunds have not been factored into the company's future outlook. Medtronic now anticipates annual organic revenue growth between 7.25% and 7.75%, up from its previous forecast of 6.75% to 7.25%.

Martha expressed confidence in Medtronic's strategic direction, emphasizing the company's focus on segments with both high growth potential and large patient bases. "We've had a steady cadence of M&A, prioritizing the higher growth segments of medtech," he stated, reflecting on the company's commitment to expanding its influence in the medical technology industry.